“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Lipid Parameters in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s115. Accessed May 17, 2025. https://skin.dermsquared.com/skin/article/view/1966.